中东和非洲分子诊断市场 – 行业趋势和 2028 年预测

市场分析与洞察：中东和非洲分子诊断市场

预计分子诊断市场将在 2021 年至 2028 年的预测期内实现市场增长。Data Bridge Market Research 分析，在 2021 年至 2028 年的预测期内，该市场将以 6.1% 的复合年增长率增长，预计到 2028 年将达到 13.882 亿美元。对诊断 COVID-19 患者的分子诊断工具的需求正在增加，再加上传染病和癌症患病率的增加，成为分子诊断市场增长的驱动力。

分子诊断通过研究组织或体液中的 DNA、RNA、蛋白质等分子来识别或诊断传染病、遗传病、心血管疾病、神经系统疾病等疾病。PCR、质谱、新一代测序、细胞遗传学、原位杂交、分子成像等不同技术可用于诊断不同的疾病。分子诊断使用基因表达谱、DNA 序列分析和生物标志物检测等强大工具来确定个体对某些疾病或现有疾病阶段的易感性。它已成为医院、临床实验室等的重要组成部分，因为它包括识别和分析疾病的所有测试和方法。它有助于为患者提供最佳治疗，而且随着新技术的出现，诊断过程变得更快、更高效。

Molecular diagnostics tools, instruments, and kits are developed to diagnose a particular or multiple diseases from body fluid or tissues. Many technological developments are launching new products with highly efficient technology to offer the best possible treatment on time. Moreover, the demand for molecular diagnostics tools increases to diagnose COVID-19 patients, coupled with an increase in infectious disease and cancer prevalence. Increasing demand for point-of-care testing is the key factor driving the Middle East & Africa molecular diagnostics market. However, the high cost of instrumentation and stringent rules laid down by governmental bodies for the approval of molecular diagnostics products may hamper the growth of the molecular diagnostics market.

Furthermore, the rise in several fundings by governmental bodies and private authorities to develop molecular diagnostics products coupled with increased healthcare expenditure and rising adoption of analyzer software for molecular diagnostics will create huge opportunities for the Middle East & Africa Molecular Diagnostics market. However, high competition in the market and disturbed supply chain due to the COVID-19 pandemic are expected to challenge the Middle East & Africa molecular diagnostics market.

The molecular diagnostics market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the Molecular diagnostics market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Molecular Diagnostics Market Scope and Market Size

The molecular diagnostics market is segmented based on the products, technology, application, and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of products, the Middle East & Africa molecular diagnostics market is segmented into reagents & kits, instruments and services & softwares. Instruments are further segmented into fully automated instruments and semi-automated instruments. In 2021, the instruments segment is expected to dominate the molecular diagnostics market due to the rise in demand for advanced technology to diagnose diseases like infectious diseases, cancer, and others.
• On the basis of technology, the Middle East & Africa molecular diagnostics market is segmented into mass spectrometry (MS), capillary electrophoresis, next generation sequencing (NGS), chips and microarray, polymerase chain reaction (PCR)-based methods, cytogenetics, in situ hybridization (ISH or FISH), molecular imaging and others. The polymerase chain reaction (PCR)-based methods are further segmented into cold PCR, digital PCR, directlinear analysis, quantitative fluorescent PCR, real-time PCR and reverse transcriptase PCR. The molecular imaging segment is further subdivided into optical imaging and FDG-PET. In 2021, the polymerase chain reaction (PCR)-based methods segment is expected to dominate the molecular diagnostics market due to increased demand for PCR kits to diagnose COVID-19 and curb the pandemic.
• On the basis of application, the Middle East & Africa molecular diagnostics market is segmented into oncology, pharmacogenomics, microbiology, prenatal tests, tissue typing, blood screening, cardiovascular diseases, neurological diseases, infectious diseases, and others. The oncology segment is further segmented into oncology, by cancer type, and oncology, by technology. The oncology, by cancer type is further sub-divided into breast cancer, colorectal cancer, lung cancer, prostate cancer, and others. The oncology, by technology, is further sub-segmented into mass spectrometry (MS), capillary electrophoresis, next generation sequencing (NGS), chips and microarray, polymerase chain reaction (PCR)-based methods, cytogenetics, in situ hybridization (ISH or FISH), molecular imaging and others. The pharmacogenomics is further segmented into mass spectrometry (MS), capillary electrophoresis, next generation sequencing (NGS), chips and microarray, polymerase chain reaction (PCR)-based methods, cytogenetics, in situ hybridization (ISH or FISH), molecular imaging and others. The microbiology is further segmented into mass spectrometry (MS), capillary electrophoresis, next generation sequencing (NGS), chips and microarray, polymerase chain reaction (PCR)-based methods, cytogenetics, in situ hybridization (ISH or FISH), molecular imaging, and others. The prenatal tests are further segmented into mass spectrometry (MS), capillary electrophoresis, next generation sequencing (NGS), chips and microarray, polymerase chain reaction (PCR)-based methods, cytogenetics, in situ hybridization (ISH or FISH), molecular imaging and others. The tissue typing is further segmented into mass spectrometry (MS), capillary electrophoresis, next generation sequencing (NGS), chips and microarray, polymerase chain reaction (PCR)-based methods, cytogenetics, in situ hybridization (ISH or FISH), molecular imaging and others. The blood screening is further segmented into mass spectrometry (MS), capillary electrophoresis, next-generation sequencing (NGS), chips and microarray, polymerase chain reaction (PCR)-based methods, cytogenetics, in situ hybridization (ISH or FISH), molecular imaging and others. The cardiovascular diseases are further segmented into mass spectrometry (MS), capillary electrophoresis, next generation sequencing (NGS), chips and microarray, polymerase chain reaction (PCR)-based methods, cytogenetics, in situ hybridization (ISH or FISH), molecular imaging and others. The neurological is further segmented into mass spectrometry (MS), capillary electrophoresis, next generation sequencing (NGS), chips and microarray, polymerase chain reaction (PCR)-based methods, cytogenetics, in situ hybridization (ISH or FISH), molecular imaging, and others. The infectious diseases are further segmented into mass spectrometry (MS), capillary electrophoresis, next-generation sequencing (NGS), chips and microarray, polymerase chain reaction (PCR)-based methods, cytogenetics, in situ hybridization (ISH or FISH), molecular imaging and others. In 2021, the infectious diseases segment is expected to dominate the molecular diagnostics market due to the rise in infectious diseases such as flu, COVID-19, AIDS, and others and the increased demand for highly efficient molecular diagnostics technology.
• On the basis of end user, the Middle East & Africa molecular diagnostics market is segmented into hospital, clinical laboratories and academics. In 2021, the clinical laboratories segment is expected to dominate the molecular diagnostics market due to the rising number of patients with various illnesses and the growing need for diagnostics instruments.

Middle East and Africa Molecular Diagnostics Market Country Level Analysis

The molecular diagnostics market is analysed, and market size information is provided by the country, products, technology, application, and end user as referenced above.

The countries covered in the Molecular diagnostics market report are the South Africa, and Rest of Middle East and Africa

Products segment in Rest of the Middle East & Africa is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of increase in demand for diagnosis instruments to diagnose COVID-19 patients and other cardiovascular diseases infectious diseases, and others. The products segment in South Africa is dominating the Middle East & Africa market owing to increased healthcare expenditure.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the significant pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East & Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Growing Strategic Activities by Major Market Players to Enhance the Awareness for Molecular diagnostics, is Boosting the Molecular diagnostics market. Growth of

The molecular diagnostics market also provides you with detailed market analysis for every country growth in particular market. Additionally, it provides the detail information regarding the market players’ strategy and their geographical presence. The data is available for historic period 2010 to 2019.

Competitive Landscape and Molecular Diagnostics Market Share Analysis

Molecular Diagnostics Market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to Molecular diagnostics market.

从事分子诊断业务的主要公司包括雅培、西门子医疗有限公司、赛默飞世尔科技公司、BD、bioMérieux SA、Cepheid、Hologic、Life Technologies、Myriad Genetics、Inc.、QIAGEN、安捷伦科技公司、Quidel Corporation、Beckman Coulter、Inc.、Bio-Rad Laboratories、Inc.、Illumina、Inc.、IMMUCOR、Luminex Corporation、Meridian Bioscience、Hoffmann-La Roche Ltd 和 GenMark Diagnostics、Inc. 以及其他国内公司。DBMR 分析师了解竞争优势，并为每个竞争对手分别提供竞争分析。

世界各地的公司也发起了许多合同、协议和发布，这也加速了分子诊断市场的发展。

例如，

• 2021 年 6 月，赛默飞世尔科技公司推出了一款名为 Attune CytPix 的新产品，这是一款荧光流式细胞仪，可通过高速摄像机提供增强成像和声学聚焦功能。
• 2020年3月，雅培推出了一款名为ID NOW的新产品，用于检测冠状病毒。它重量轻、便携、准确度高，并采用分子技术。

市场参与者的合作、产品发布、业务扩展、奖励和认可、合资企业等策略正在增强公司在分子诊断市场的影响力，这也为组织的利润增长带来了好处。

SKU-64283